Jennifer L. Guerriero

The paper analyzes HER2+ breast cancer using multi-platform data to identify molecular predictors of response to neoadjuvant therapy and highlights intra-tumoral heterogeneity and immune exclusion mechanisms.

The paper shows BRCA-mutant breast cancers respond to PARP inhibitors with immune remodeling, but PD-L1 blockade is ineffective due to spatial separation of PD-L1+ cells and PD-1+ T cells.

This study identifies tumor-myeloid crosstalk as a driver of cisplatin resistance in bladder cancer and proposes PARP14 inhibition as a therapeutic strategy.

The paper identifies distinct immune and stromal features in HR+ HER2-low and HER2-0 breast cancers using molecular and multiplexed imaging.

The paper examines how platinum-based chemotherapy affects tumor immune microenvironments in urothelial cancer, finding that memory B cell infiltration correlates with improved survival in cisplatin-treated patients.

The paper identifies four immunomodulatory programs in glioma-associated myeloid cells using scRNA-seq and shows they are driven by microenvironmental cues and therapies, not cell type or mutation status.

This study identifies an estrogen receptor signaling program in HR+ breast cancer that suppresses immune responses by reducing T cell infiltration and HLA expression, suggesting therapeutic targets to enhance immunogenicity.

This paper introduces CyLinter, a quality control tool that removes imaging artefacts from high-plex spatial profiling data, improving single-cell analysis of archival tumor specimens.